Y-Intercept (HK)’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Y-Intercept (HK)’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-78,576	Closed	-$3.21M	–	1926
2024 Q2	$3.21M	Buy	+78,576	New	+$3.27M	0.18%	124
2023 Q1	–	Sell	-13,491	Closed	-$426K	–	1629
2022 Q4	$426K	Buy	+13,491	New	+$381K	0.06%	494

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Y-Intercept (HK)'s CERE Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 78,576 shares — an estimated $3.21M sold.

Y-Intercept (HK) first reported a position in CERE in Q4 2022 and held it in 2 quarters. The position peaked at $3.21M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Y-Intercept (HK) reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Y-Intercept (HK) sold 78,576 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $3.21M.
Y-Intercept (HK) first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Y-Intercept (HK)'s Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3.21M in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.